Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lawsuit Will Question Supplement Exclusion From Lycopene/Cancer Claims

This article was originally published in The Tan Sheet

Executive Summary

American Longevity will file a lawsuit against FDA no later than Dec. 9 in response to the agency's denial of qualified health claims tying lycopene-containing dietary supplements to cancer risk reduction

You may also be interested in...



Emord Extends Effort To Liberalize QHCs With Selenium, Antioxidant Petitions

Attorney Jonathan Emord continues his effort to force FDA to allow more expansive qualified health claims for nutritional supplements with two petitions relating to the capability of selenium and antioxidant vitamins to reduce the risk of site-specific cancers

Emord Extends Effort To Liberalize QHCs With Selenium, Antioxidant Petitions

Attorney Jonathan Emord continues his effort to force FDA to allow more expansive qualified health claims for nutritional supplements with two petitions relating to the capability of selenium and antioxidant vitamins to reduce the risk of site-specific cancers

Emord Extends Effort To Liberalize QHCs With Selenium, Antioxidant Petitions

Attorney Jonathan Emord continues his effort to force FDA to allow more expansive qualified health claims for nutritional supplements with two petitions relating to the capability of selenium and antioxidant vitamins to reduce the risk of site-specific cancers

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS098830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel